A five-year-old Shanghai startup with no approved product yet is heading toward the stock market — and its filing paperwork reads like a progress report on China's brain-computer interface industry.
Jieti Medical (阶梯医疗), formally Shanghai Jieti Medical Technology, submitted an IPO tutoring (上市辅导) filing to the Shanghai regulatory bureau of the China Securities Regulatory Commission on November 2, with Huatai United Securities as its tutoring institution, according to disclosures reported by Securities Daily and other outlets. The tutoring agreement was signed on October 30. The company completed its conversion into a joint-stock company in September, a standard step before listing.
To be precise about where this stands: IPO tutoring is the earliest formal stage of a mainland China listing process, in which a sponsor trains and vets the company ahead of an application. It is not an approved listing, and there is no guarantee the company will ultimately file or list.
The clinical file behind the filing
What makes the filing notable is the evidence base Jieti brings to it. According to the company disclosures cited in the reports:
- As of late October, the company had completed 42 long-term implantations of its fully invasive brain-computer interface — characterized in Chinese media reports as the most among fully invasive BCI companies globally, exceeding the 27 publicly reported by Neuralink, though such comparisons rely on voluntary disclosures.
- Cumulative in-body time across trial participants exceeds 5,000 days.
- Cumulative brain-control usage time exceeds 10,000 hours.
- Its core product, the WRS 01 system — a 256-channel minimally invasive implanted BCI aimed at rebuilding motor function for patients with high-level paralysis — has entered registration-stage clinical trials, completed full enrollment of its multi-center trial in August, and was the first fully invasive BCI product admitted into the NMPA's innovative medical device special review channel.
- In cursor-control testing, signal-to-command latency is below 0.05 seconds, with peak information transfer rates of 390 bits per minute — performance the company says approaches that of an unimpaired computer user.
The company was founded in August 2021 by Zhao Zhengtuo and Li Xue, both born in the 1990s and trained in biomedical engineering at the University of Texas at Austin and Rice University respectively; Zhao leads a neural interface research group at the Chinese Academy of Sciences' Center for Excellence in Brain Science and Intelligence Technology. The couple jointly control about 36.35% of shares.
Capital has already voted
Jieti's move to IPO follows a heavy funding run. Per the reported disclosures, the company has raised a cumulative 2.6 billion yuan (about US$361 million) — the highest cumulative financing among China's invasive BCI companies, according to Securities Daily-linked reporting. Key rounds include:
- A 500 million yuan (about US$69 million) strategic round in March 2026, led by Alibaba with participation from Tencent — an unusual joint bet by China's two internet giants on the same BCI company.
- Roughly 1.4 billion yuan (about US$194 million) raised in the second half of 2026, with investors including CATL, Geely Capital, CDH Investments and state-backed funds.
Jieti is not moving alone. BoRuiKang (博睿康), whose NEO system became the world's first approved invasive BCI medical device in March, as described in press reports, has already had its STAR Market (科创板) IPO application accepted, and brain-training hardware maker BrainCo (强脑科技) is among other companies progressing toward capital markets. Shanghai's science authorities said at a recent briefing that three local BCI companies are pursuing IPOs, within a city cluster of more than 120 BCI firms that raised over 4 billion yuan (about US$556 million) this year.
Why a listing race matters for patients
The financialization of the sector changes its economics in concrete ways:
- Longer time horizons. Registration trials and post-market surveillance for implanted devices run for years; public-market capital can fund that runway better than successive venture rounds.
- Mandatory disclosure. A listed Jieti would have to publish clinical, financial and risk data on a fixed schedule — a transparency shift for a field that currently communicates through briefings and press releases.
- Validation of the payor path. The sector's commercial thesis increasingly rests on insurance coverage, such as Shanghai's Huibao (沪惠保) reimbursing up to 30% of the approved NEO system's cost.
The market sizing so far is modest by tech standards. The China Academy of Information and Communications Technology (CAICT, 中国信通院) forecasts China's BCI market at about 12 billion yuan (about US$1.67 billion) by 2030, up from roughly 3 billion yuan (about US$417 million) in 2025 — a signal that investors are pricing clinical adoption curves, not consumer gadgets.
Honest limitations
- The 42-implant figure and "global most among fully invasive companies" characterization come from company disclosures and Chinese media reports, including a comparison with Neuralink's publicly reported 27 implants; neither company's numbers are independently audited, and definitions of "long-term implantation" may differ.
- Performance metrics such as 390 bits per minute and sub-0.05-second latency are company-reported testing results, not peer-reviewed data.
- The IPO process is at the tutoring stage only; the timeline, listing venue and final terms remain undetermined, and tutoring does not ensure registration approval.
- CAICT's 2030 market forecast is a single institution's projection and has a wide error band inherent to emerging-technology forecasting.
What readers can do now
- Investors tracking the sector can follow the CSRC's IPO tutoring disclosure system, where Jieti's tutoring progress and any subsequent prospectus will appear before any listing decision.
- Clinicians and researchers can watch WRS 01's multi-center registration trial readouts, since efficacy and safety data — not financing totals — will determine regulatory outcomes.
- Policy analysts may find the sector's capital wave a useful test case for how China's "future industries" framework, which includes BCI in the 15th Five-Year Plan (十五五规划), translates into capital-market activity.
